Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 3/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9720787 | 0.90 | ESR2 (0.42) | PDCD1CD274ENPP1PDK2MAP4K4 | |
| SCHEMBL9720784 | 0.88 | ESR2 (0.43) | PDCD1CD274ENPP1PDK2GCGR | |
| SCHEMBL9720758 | 0.88 | PDCD1 (0.41) | PDCD1CD274ENPP1PDK2PRKAA2 | |
| SCHEMBL9720754 | 0.86 | PDCD1 (0.42) | PDCD1CD274ENPP1PDK2PRKAA2 | |
| SCHEMBL27555128 | 0.85 | TTR (0.43) | PDCD1CD274ENPP1PDK2PRKAA2 | |
| SCHEMBL1443909 | 0.83 | ENPP1 (0.39) | ENPP1PTGS1SLC6A4SLC6A3PTGS2 | |
| SCHEMBL11494835 | 0.82 | MMP3 (0.49) | PDCD1CD274PDK2ABL1 | |
| SCHEMBL13824010 | 0.82 | NR4A2 (0.48) | PDCD1CD274ENPP1PDK2PTGS1 | |
| SCHEMBL1041243 | 0.82 | PDK2 (0.49) | PDCD1CD274PDK2PTGS1SLC6A4 | |
| SCHEMBL7204765 | 0.82 | PDCD1 (0.62) | PDCD1CD274ENPP1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286389-B2 | Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof | Shenzhen Jingtai Technology Co., Ltd (CN) | 2025-04-29 | — | — | US | disclosed |
| US-20220033347-A1 | CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Jingtai Technology Co., Ltd (CN) | 2022-02-03 | — | — | US | disclosed |
| WO-2011034860-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1968563-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1158971-B1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007075849-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1158971-A4 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1158971-A1 | GARDOS CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6288122-B1 | A TRIPHENYL ACETAMIDE | ICAGEN, INC. | 2001-09-11 | — | — | US | disclosed |
| WO-2000050026-A1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| US-5149707-A | 1-((2-FLUOROPHENYL)(4-FLUOROPHENYL)PHENYLMETHYL)-1H-IMIDAZOLE USEFUL AS ANTIFUNGAL AGENT | J. URIACH & CIA, S.A. (ES) | 1992-09-22 | — | — | US | disclosed |
| EP-0352352-B1 | 1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole | J. URIACH & CIA. S.A. (ES) | 1991-10-16 | — | — | EP | disclosed |
| EP-0352352-A1 | 1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole | J. URIACH & CIA. S.A. (ES) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | KCNH3, KCNH2, KCNJ2 | PDCD1 2723/4885CD274 3480/4885ENPP1 3912/4885 |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | KCNH3, KCNH2, KCNJ2 | PDCD1 2723/4885CD274 3480/4885ENPP1 3912/4885 |
| US-12286389-B2 | Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof | WEE2, WEE1, WASF2 | PDCD1 2854/4885CD274 3704/4885ENPP1 3934/4885 |
| US-20220033347-A1 | CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE2, WEE1, WASF2 | PDCD1 2854/4885CD274 3704/4885ENPP1 3934/4885 |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | LTC4S, LTB4R2, CYSLTR2 | PDCD1 4522/4885CD274 4658/4885ENPP1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.